Prevalence

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

Sunday, September 26, 2021 - 12:00pm

The SEED study is a Phase III registered clinical study of dorzagliatin monotherapy in drug-naive Type 2 diabetes patients to observe its long-term efficacy and safety.

Key Points: 
  • The SEED study is a Phase III registered clinical study of dorzagliatin monotherapy in drug-naive Type 2 diabetes patients to observe its long-term efficacy and safety.
  • The researchers comprehensively evaluated the subjects and set their individual HbA1c control goals, and the results of the research showed that the subjects had a 52-week glucose remission rate of 65.2% (95% CI, 53.4%, 77.0%) [1] during the research period.
  • The DREAM study explores the possibility of oral dosing in diabetes remission and is of great significance in expanding the treatment options for Type 2 diabetes."
  • Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive, degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes.

FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

Saturday, September 25, 2021 - 1:09am

The approval is based on the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha in pediatric patients, 10 - 17 years of age, with HeFH.

Key Points: 
  • The approval is based on the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha in pediatric patients, 10 - 17 years of age, with HeFH.
  • The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients.
  • Repatha was already approved for treatment in HoFHpatients aged 13 and older and is now available as a treatment for patients aged 10 and older.
  • Randomization was stratified by LDL-C (

Europe Diabetic Nephropathy Market and Competitive Landscape Report 2021: Pipeline, Epidemiology, Valuations, Sales, Drug Forecasts, and Market Shares 2018-2026 - ResearchAndMarkets.com

Friday, September 24, 2021 - 2:54pm

The "Europe Diabetic Nephropathy Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Diabetic Nephropathy Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Diabetic Nephropathy Market and Competitive Landscape - 2021, provides comprehensive insights into the Diabetic Nephropathy pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Diabetic Nephropathy treatment options, Diabetic Nephropathy late-stage clinical trials pipeline, Diabetic Nephropathy prevalence by countries, Diabetic Nephropathy market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Diabetic Nephropathy pipeline: Find out drugs in clinical trials for the treatment of Diabetic Nephropathy by development phase 3, phase 2, by pharmacological class and company
    Diabetic Nephropathy drugs: Identify key drugs marketed and prescribed for Diabetic Nephropathy in the US, including trade name, molecule name, and company
    Diabetic Nephropathy market valuations: Find out the market size for Diabetic Nephropathy drugs in 2020 by countries.

Europe Migraine Market and Competitive Landscape Report 2021: Pipeline, Epidemiology, Valuations, Sales, Drug Forecasts, and Market Shares 2018-2026 - ResearchAndMarkets.com

Friday, September 24, 2021 - 2:53pm

The "Europe Migraine Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Migraine Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Migraine Market and Competitive Landscape - 2021, provides comprehensive insights into Migraine pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts Migraine market size and drug sales.
  • This research covers the following - Migraine treatment options, Migraine late-stage clinical trials pipeline, Migraine prevalence by countries, Migraine market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.

Europe Irritable Bowel Syndrome Market and Competitive Landscape Report 2021: Pipeline, Epidemiology, Valuations, Sales, Drug Forecasts, and Market Shares 2018-2026 - ResearchAndMarkets.com

Friday, September 24, 2021 - 2:45pm

The "Europe Irritable Bowel Syndrome Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Irritable Bowel Syndrome Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Irritable Bowel Syndrome Market and Competitive Landscape - 2021, provides comprehensive insights into Irritable Bowel Syndrome pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Irritable Bowel Syndrome treatment options, Irritable Bowel Syndrome late-stage clinical trials pipeline, Irritable Bowel Syndrome prevalence by countries, Irritable Bowel Syndrome market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Irritable Bowel Syndrome pipeline: Find out drugs in clinical trials for the treatment of Irritable Bowel Syndrome by development phase 3, phase 2, by pharmacological class and company
    Irritable Bowel Syndrome drugs: Identify key drugs marketed and prescribed for Irritable Bowel Syndrome in the US, including trade name, molecule name, and company
    Irritable Bowel Syndrome drugs sales: Find out the sales value for Irritable Bowel Syndrome drugs by countries
    Irritable Bowel Syndrome market valuations: Find out the market size for Irritable Bowel Syndrome drugs in 2020 by countries.

Global Wilson's Disease Market and Competitive Landscape Report 2021: Pipeline, Epidemiology, Valuations, Sales, Drug Forecasts, and Market Shares 2018-2026 - ResearchAndMarkets.com

Friday, September 24, 2021 - 2:36pm

The "Global Wilson's Disease Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Wilson's Disease Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Wilson's Disease Market and Competitive Landscape - 2021, provides comprehensive insights into Wilson's Disease pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Wilson's Disease treatment options, Wilson's Disease late-stage clinical trials pipeline, Wilson's Disease prevalence by countries, Wilson's Disease market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Wilson's Disease pipeline: Find out drugs in clinical trials for the treatment of Wilson's Disease by development phase 3, phase 2, by pharmacological class and company
    Wilson's Disease drugs: Identify key drugs marketed and prescribed for Wilson's Disease in the US, including trade name, molecule name, and company
    Wilson's Disease market valuations: Find out the market size for Wilson's Disease drugs in 2020 by countries.

Europe Esophageal Cancer Market and Competitive Landscape Report 2021: Pipeline, Epidemiology, Valuations, Sales, Drug Forecasts, and Market Shares 2018-2026 - ResearchAndMarkets.com

Friday, September 24, 2021 - 2:33pm

The "Europe Esophageal Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Esophageal Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Esophageal Cancer Market and Competitive Landscape - 2021, provides comprehensive insights into Esophageal Cancer pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Esophageal Cancer treatment options, Esophageal Cancer late-stage clinical trials pipeline, Esophageal Cancer prevalence by countries, Esophageal Cancer market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Esophageal Cancer pipeline: Find out drugs in clinical trials for the treatment of Esophageal Cancer by development phase 3, phase 2, by pharmacological class and company
    Esophageal Cancer drugs: Identify key drugs marketed and prescribed for Esophageal Cancer in the US, including trade name, molecule name, and company
    Esophageal Cancer market valuations: Find out the market size for Esophageal Cancer drugs in 2020 by countries.

Europe Gastro-Intestinal Stromal Tumors Market and Competitive Landscape Report 2021: Pipeline, Epidemiology, Valuations, Sales, Drug Forecasts, and Market Shares 2018-2026 - ResearchAndMarkets.com

Friday, September 24, 2021 - 2:32pm

The "Europe Gastro-Intestinal Stromal Tumors Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Gastro-Intestinal Stromal Tumors Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Gastro-Intestinal Stromal Tumors Market and Competitive Landscape - 2021, provides comprehensive insights into Gastro-Intestinal Stromal Tumors pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Gastro-Intestinal Stromal Tumors treatment options, Gastro-Intestinal Stromal Tumors late-stage clinical trials pipeline, Gastro-Intestinal Stromal Tumors prevalence by countries, Gastro-Intestinal Stromal Tumors market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Gastro-Intestinal Stromal Tumors pipeline: Find out drugs in clinical trials for the treatment of Gastro-Intestinal Stromal Tumors by development phase 3, phase 2, by pharmacological class and company
    Gastro-Intestinal Stromal Tumors drugs: Identify key drugs marketed and prescribed for Gastro-Intestinal Stromal Tumors in the US, including trade name, molecule name, and company
    Gastro-Intestinal Stromal Tumors drugs sales: Find out the sales value for Gastro-Intestinal Stromal Tumors drugs by countries
    Gastro-Intestinal Stromal Tumors market valuations: Find out the market size for Gastro-Intestinal Stromal Tumors drugs in 2020 by countries.

Europe Soft Tissue Sarcoma Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Friday, September 24, 2021 - 2:23pm

The "Europe Soft Tissue Sarcoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Soft Tissue Sarcoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Soft Tissue Sarcoma Market and Competitive Landscape - 2021, provides comprehensive insights into Soft Tissue Sarcoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Soft Tissue Sarcoma treatment options, Soft Tissue Sarcoma late-stage clinical trials pipeline, Soft Tissue Sarcoma prevalence by countries, Soft Tissue Sarcoma market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Soft Tissue Sarcoma pipeline: Find out drugs in clinical trials for the treatment of Soft Tissue Sarcoma by development phase 3, phase 2, by pharmacological class and company
    Soft Tissue Sarcoma drugs: Identify key drugs marketed and prescribed for Soft Tissue Sarcoma in the US, including trade name, molecule name, and company
    Soft Tissue Sarcoma drugs sales: Find out the sales value for Soft Tissue Sarcoma drugs by countries
    Soft Tissue Sarcoma market valuations: Find out the market size for Soft Tissue Sarcoma drugs in 2020 by countries.

4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting

Friday, September 24, 2021 - 12:03pm

4DMT is currently enrolling patients in an on-going Phase 1/2 dose-escalation and dose-expansion clinical trial assessing intravitreal 4D-125, 4DMTs targeted and evolved R100-based product candidate for XLRP.

Key Points: 
  • 4DMT is currently enrolling patients in an on-going Phase 1/2 dose-escalation and dose-expansion clinical trial assessing intravitreal 4D-125, 4DMTs targeted and evolved R100-based product candidate for XLRP.
  • Patients are enrolled in one of two dose cohorts: 3E11 vg/eye and 1E12 vg/eye.
  • The primary objectives of this trial are to evaluate the safety and maximum tolerated dose of 4D-125.
  • 4D Molecular Therapeutics, 4DMT, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.